Ketamine for depression: all studies (page 152)

Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics.

Journal of experimental neuroscience September 19, 2018 David E. Olson

Neural plasticity-the ability to change and adapt in response to stimuli-is an essential aspect of healthy brain function and, in principle, can be harnessed to promote recovery from a wide variety of brain disorders. Many neuropsychiatric diseases including mood, anxiety, and substance use disorders arise from an inability to weaken and/or strengthen pathologic and beneficial circuits,...

DOI: 10.1177/1179069518800508 Full text Depression Ketamine MDMA PTSD +6

Early life stress leads to sex differences in development of depressive-like outcomes in a mouse model.

Neuropsychopharmacology September 6, 2018 Haley L Goodwill, Gabriela Manzano-Nieves, Meghan Gallo et al.

Childhood trauma and neglect influence emotional development and increase the risk for and severity of mental illness. Women have a heightened susceptibility to the effects of early life stress (ELS) and are twice as likely as men to develop debilitating, stress-associated disorders later in life, such as major depressive disorder (MDD). Until now, mouse models of depression have been largely...

DOI: 10.1038/s41386-018-0195-5 Full text Ketamine Depression Animals Mice, inbred c57bl +7

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.

Neuropharmacology September 1, 2018 Dylan Chou, Hsien-Yu Peng, Tzer-Bin Lin et al.

It has been widely reported that ketamine rescues chronic stress-induced depression-like behavior, but the underlying cellular mechanisms of the rapid antidepressant actions of ketamine remain largely unclear. Both male and female Sprague-Dawley rats were used and received modified learned helplessness paradigm to induce depression-like behavior. Depression-like behavior was assayed and...

DOI: 10.1016/j.neuropharm.2018.06.033 Full text Depression Ampa receptor Chronic stress Electrophysiology +1

Subanesthetic ketamine reverses neuronal and astroglial metabolic activity deficits in a social defeat model of depression.

Journal of Neurochemistry September 2018 Pravin K Mishra, Arvind Kumar, Kevin L. Behar et al.

Depression is one of the most debilitating neuropsychiatric disorders. Most of the current antidepressants have long remission time and low recovery rate. This study explores the impact of ketamine on neuronal and astroglial metabolic activity in prefrontal cortex in a social defeat (SD) model of depression. C57BL/6 mice were subjected to a social defeat paradigm for 5 min a day for 10...

DOI: 10.1111/jnc.14544 Full text Glutamate Glutamine Neuron-glia interaction Neurotransmission +1

Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

Journal of Child and Adolescent Psychopharmacology September 2018 Kathryn R. Cullen, Palistha Amatya, Mark G Roback et al.

Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. Adolescents, 12-18 years of age, with TRD (failure to...

DOI: 10.1089/cap.2018.0030 Full text Depression Ketamine Adolescent Treatment-resistant

Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research September 1, 2018 Li Ren, Jie Deng, S. Min et al. 48 citations

Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorder. Sub-anesthetic dose of ketamine exerts a rapid and robust antidepressive effect. However, it is still unclear whether ketamine usage in ECT is efficacious as an antidepressant. We aimed to conduct a systematic review and meta-analysis on the effects of ketamine in ECT among patients with depressive...

DOI: 10.1016/j.jpsychires.2018.07.003

Comparative study of esketamine and racemic ketamine in treatment-resistant depression

Medicine September 1, 2018 Fernanda S. Correia-Melo, Gustavo C. Leal, Michelle S. Carvalho et al. 61 citations

INTRODUCTION: The use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better...

DOI: 10.1097/md.0000000000012414

Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.

Journal of Affective Disorders August 15, 2018 Patricio Riva-Posse, Collin Reiff, Johnathan A Edwards et al.

The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication. There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety. There is limited data about the cardiovascular safety of...

DOI: 10.1016/j.jad.2018.02.025 Full text

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.

Journal of Affective Disorders August 1, 2018 Somaye Arabzadeh, Elham Hakkikazazi, Nazila Shahmansouri et al.

Major depressive disorder (MDD) exerts a high health and financial burden on society. The conventional pharmacotherapies for MDD are partially effective and the response to medication often starts with some delay. There are recent reports of antidepressant effects for oral ketamine. We employed a double-blind controlled trial to examine the time course of the therapeutic effect of ketamine when...

DOI: 10.1016/j.jad.2018.02.056 Full text Depression Adjunctive therapy Hdrs Oral ketamine

7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study.

Neuropsychopharmacology August 2018 Jennifer W. Evans, Níall Lally, Li An et al.

The glutamatergic modulator ketamine has striking and rapid antidepressant effects in major depressive disorder (MDD), but its mechanism of action remains unknown. Proton magnetic resonance spectroscopy (1H-MRS) is the only non-invasive method able to directly measure glutamate levels in vivo; in particular, glutamate and glutamine metabolite concentrations are separable by 1H-MRS at 7T. This...

DOI: 10.1038/s41386-018-0057-1 Full text